The NuMED 10-zig Covered CP (CCP) balloon expandable covered stent. It is used for repair of sinus venosus atrial septal defects (SVASD). #SVASD #SCAI2021 #congenitalheart #
May 01, 2021
Global registry Shows Longer Stent Minimizes Procedure Complications in Sinus Venosus Atrial Septal Defects
May 1, 2021 - An analysis of a new international registry reveals benefits of using a longer covered stent for…
Read More
The Medtronic Harmony transcatheter pulmonary valve (TPV) system offers a less invasive treatment option for patients with a congenital heart defect irregularity in their right ventricular outflow tract (RVOT) that requires a pulmonary valve placement to restore valve function. 
Dave Fornell, Editor
April 30, 2021
One-year Results of the Harmony Transcatheter Pulmonary Valve Trial Presented at SCAI 2021 
April 30, 2021 — New study results validate the effectiveness of the Medtronic Harmony transcatheter pulmonary valve (…
Read More
The two FDA-clear transcatheter aortic valve replacement (TAVR) valves on the market, the Edwards Lifesciences Sapien 3 (left) and the Medtronic CoreValve (right).
April 30, 2021
TAVR Access is Inequitable Based Socioeconomics Level and Geography
April 30, 2021 – An analysis of growth patterns in transcatheter aortic valve replacement (TAVR) programs across United…
Read More
New study demonstrates depression, HIV, mental health, obesity, alcohol and drug abuse are risk factors on most common type of heart disease in young black patients. Photo by Dave Fornell
April 29, 2021
Young African Americans With Coronary Disease Impacted by Non-traditional Risk Factors
April 29, 2021 – A retrospective analysis of risk factors for coronary artery disease (CAD) in young African American…
Read More
The Abiomed Impella percutaneous heart pump was shown in the NCSI study to greatly improve survival of acute myocardial infarction with cardiogenic shock (AMICS), raising survival from 50 percent to 71 percent. Ambulance image from Getty Images.
By Dave Fornell, Editor
April 29, 2021
National Cardiogenic Shock Initiative Protocol Shows 71 Percent Survival 
April 29, 2021 — The results of a large, national heart attack study show that patients with  cardiogenic shock…
Read More
A Chinese registry study found there are higher event rates in patients with shorter dual-antiplatelet therapy (DAPT) after PCI procedures. There has been a lot of movement toward using shorter duration DAPT with newer generation drug-eluting stent technologies, but this study reinforces the need longer DAPT in many patients. The findings were presented as a late-breaking trial at SCAI 2021 today. 
April 28, 2021
Long-term Dual Antiplatelet Therapy Benefits Reinforced in SCAI Late-breaking Study
April 28, 2021 — An analysis of the prospective Chinese Fuwai PCI Registry, confirms long-term, dual-antiplatelet…
Read More
The STAT2 trial used a combination of the Biolife Statseal potassium ferrate hemostatic patch and a Terumo TR Band to reduce radial access arteriotomy site hemostasis by 50 percent.
Dave Fornell, Editor
April 28, 2021
Radial Hemostasis Time Cut by 50 Percent With StatSeal in Combination With TR Band
April 28, 2021 — A new study reveals the use of a potassium ferrate hemostatic patch (PFHP) reduces the time to…
Read More
There are far fewer patients coming to hospitals with heart attacks during the COVID-19 pandemic as compared to averages prior to the pandemic. This has raised concerns that delayed treatment will cause an uptick in cardiac deaths and heart failure. Photo from Getty Images 
April 28, 2021
COVID Caused Major Decline in Heart Attack Patients Seeking Care
April 28, 2021 – Results from a retrospective observational study, presented today at Society for Cardiovascular…
Read More
A cardiac cath lab at Henry Ford Hospital in Detroit. Photo by Dave Fornell
April 28, 2021
SCAI Updates Best Practices in the Cardiac Cath Lab Guidelines Document
April 28, 2021 — The Society for Cardiovascular Angiography and Interventions (SCAI) has released an expert consensus…
Read More
Patients receiving an implantable cardioverter defibrillator (ICD) should be regularly screened for anxiety and depression, according to research presented at European Heart Rhythm Association (EHRA) 2021 conference. ICD depression
April 26, 2021
Study Shows Risks of Anxiety and Depression After Cardiac Device Implantation
April 26, 2021 — Patients receiving an implantable cardioverter defibrillator (ICD) should be regularly screened for…
Read More
Racism and heart disease. This study looks at heart failure patients and the impact of socioeconomic disparities associate with epigenetics. The study looks to overcome preconcieved ideas about race in cardiac studies by looking at underlaying causes for the disease. Image courtesy of the American Journal of Physiology
April 26, 2021
Socioeconomic Disparities Associate With Epigenetics and Heart Failure Outcomes
April 26, 2021 – Cardiovascular diseases are the leading cause of death in the United States. Heart failure…
Read More
Transesophageal echo (TEE) being used to guide the deployment of a MitraClip device during a structural heart procedure at the University of Colorado Hospital. The center has performed more than 200 MitraClip mitral valve repairs over the past decade. Photo by Dave Fornell
April 22, 2021
Advice For Hospitals Starting a Structural Heart Program
The resounding success of transcatheter aortic valve replacement (TAVR) has led the creation of hundreds of structural…
Read More
The FDA’s market clearance occurred once the agency reviewed EnsiteVascular’s Section 510(k) premarket notification of intent to market the SiteSeal SV device and determined it is substantially equivalent for the indication for use stated: brachial artery closure. Previously, EnsiteVascular received FDA market clearance for SiteSeal SV for radial artery closure.
April 21, 2021
FDA Clears SiteSeal SV Vascular Closure Device for the Brachial Arteries
April 21, 2021 — EnsiteVascular announced it received its second U.S. Food and Drug Administration (FDA) market…
Read More
April 20, 2021
North American COVID-19 STEMI Research Reveals High Mortality and Atypical Symptoms
April 20, 2021 – The Minneapolis Heart Institute Foundation (MHIF) announced the first publication of outcomes from the…
Read More
The reSept ASD Occluder is the first structural heart occluder with a metal-free, bioresorbable frame. The novel implant is designed to overcome the limitations of current transcatheter occluders. It is hoped the design will reduce the risk of complications associated with the long-term presence of metal in the heart and to preserve future treatment options requiring transseptal intervention.
April 20, 2021
Bioresorbable ASD Occluder Prepares to Enter U.S. Clinical Trial
April 20, 2021 — Start-up medical device company atHeart Medical announced it is initiating its U.S. investigational…
Read More
Former Vice President Mike Pence. Photo by Airman 1st Class Aubree Owens, 30th Space Wing Public Affairs
April 19, 2021
Former Vice President Mike Pence Has Pacemaker Implanted
April 19, 2021 — Former Vice President Mike Pence is recovering after having a pacemaker successfully implanted to…
Read More
Rhythm Therapeutics gene, stem cell, therapy for atrial fibrillation.
April 19, 2021
Gene Therapy for Atrial Fibrillation Will Be Investigated With $3.67 million NIH Grant
April 19, 2021 — National Heart, Lung, and Blood Institute (NHLBI) has awarded a grant for $462,689 to Rhythm…
Read More
The Elixer Dynamx Coronary Bioadaptor Stent technology uses a bioresorbable polymer that dissolves after three months and disconnected joints between numerous stent segments, allowing it to articulate and share to the vessel and movement.
April 14, 2021
First Patient Treated in Elixer Dynamx Coronary Bioadaptor Stent Technology
April, 14, 2021 – Elixir Medical recently announced the first patient was treated in the BIOADAPTOR randomized…
Read More
The U.S. Food and Drug Administration (FDA) cleared the Acutus Medical AcQCross family of universal transseptal crossing devices. This is the only transseptal puncture system specifically engineered to pair and mate seamlessly with Acutus’ own suite of sheaths and with sheaths sold by other manufacturers. 
April 14, 2021
FDA Clears Acutus Medical AcQCross Suite of Transseptal Crossing Devices
April 14, 2021 — The U.S. Food and Drug Administration (FDA) cleared the Acutus Medical AcQCross family of universal…
Read More
CDC and FDA Call for Pause on Janssen COVID-19 Vaccine Due to Rare Blood Clots #COVID19 #Janssen
By Dave Fornell, Editor
April 13, 2021
CDC and FDA Call for Pause on Janssen COVID-19 Vaccine Due to Rare Blood Clots
(This story was updated May 7, 2021 in the last subheaded section) April 13, 2021 — The U.S. Food and Drug…
Read More
© Copyright Wainscot Media. All Rights Reserved.
Subscribe Now